The independent British film, "Starfish", is released to theaters next week is based on the experience of Tom Ray who survived sepsis. At the age of 38, after a lifetime of good health, he contracted sepsis overnight after a trip to the dentist. Both of his arms and both of his legs were amputated, and most of his face was removed. After five months in a coma, he woke to find that he had a new baby son. The movie chronicles his experience including rehabilitation and subsequent re-adjustment of family life. The UK Sepsis Trust worked with various producers and distributors to make this movie happen. More information about Tom's story and trailers of the movie can be found on Twitter @starfishthefilm and starfish.film. If you get a chance watch the trailer its powerful and should be a great tool to raise awareness worldwide.
NASDAQ shows an 11/11 date for the next scheduled earnings release. Earnings Whisper site shows 11/9. In any event there could be some real volatility either up or down this close after the election results.
Product registration for Russia was completed in Q2, and INTENSIVMED started marketing it immediately. Let's hope this is evidence they are seeing the traction that they anticipated and this will translate into having some impact in Q3 sales. From the May 2016 press release:
"Mr. Victor Gorobets, CEO of INTENSIVMED LLC stated, "We are excited to announce that the registration of CytoSorb® in Russia has been successfully obtained. We will begin marketing CytoSorb® immediately in the Russian medical market, and predict strong interest with doctors for this unique therapy. CytoSorb® is a breakthrough in the modern medical world, opening new horizons in treating the most challenging conditions, such as sepsis, septic shock and the systemic inflammatory response syndrome (SIRS), with the goal of attenuating severe inflammation and successfully preventing organ failure. This innovative technology brings healthcare standards to a new level and we are proud to be its beacon in Russia."
INTENSIVMED has an ambitious near-term marketing agenda and has already been exhibiting CytoSorb® at the 13th All-Russia Scientific-Methodical conference on "Standards and Individual Approaches in Anesthesiology and Resuscitation" in southern Russia this month. It will also be an active partner of the 10th Jubilee International Conference in Moscow, Russia on June 3-4, 2016. This year, the conference will be focused on the "Actual Aspects of Extracorporeal Blood Purification in Intensive Care," and is expected to provide an excellent forum to highlight CytoSorb®. Dr. Zsolt Molnar from University of Szeged, Hungary will discuss his experiences with CytoSorb®, while other distinguished speakers will discuss the expanding role of extracorporeal blood purification in the ICU."
Thanks Bertha. This news only validates CTSO had the better business strategy of prioritizing getting CE Mark approval early on. Also, the upcoming negotiations and discussions with the FDA regarding the path for the REFRESH trial will also be very interesting on the heels of this news.
"Spectral Medical Inc said its experimental treatment for sepsis - a common, oft-deadly complication of infection - failed a late-stage study, stymieing the company's plans to bring to market the first FDA-approved device for the condition....The trial did not meet the main goal of absolute reduction in mortality rate at 28 days, Spectral said on Monday."